A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease (ILLUSTRATE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00134173|
Recruitment Status : Completed
First Posted : August 24, 2005
Last Update Posted : December 10, 2007
The Torcetrapib project was terminated on December 2, 2006 due to safety findings.
To look at ultrasound images taken in the blood vessels of the heart and to look at various lipids in the blood of people with known coronary heart disease
|Condition or disease||Intervention/treatment||Phase|
|Coronary Disease Coronary Arteriosclerosis Hyperlipidemia||Drug: torcetrapib/atorvastatin Drug: atorvastatin||Phase 3|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||1100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Phase 3, Multi-Center, Double-Blind, Randomized, Parallel Group, Coronary Artery Intravascular Ultrasound Evaluation of the Anti-Atherosclerotic Efficacy, Safety, and Tolerability of Fixed Combination CP-529,414/Atorvastatin, Administered Orally, Once Daily (QD) for 24 Months, Compared With Atorvastatin Alone, in Subjects With Angiographically Documented Coronary Heart Disease.|
|Study Start Date :||October 2003|
|Actual Study Completion Date :||September 2006|
- Change coronary artery atheroma volume as measured by intravascular ultrasound.
- Changes in levels of lipids and other biomarkers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00134173
|Study Director:||Pfizer CT.gov Call Center||Pfizer|